Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Fresenius Medical Care Corporation(FMS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FMS
10/30/2026: FMS (1-star) is currently NOT-A-BUY. Pass it for now.
Fresenius Medical Care is a global leader in renal dialysis services and medical technology, operating a critical network of clinics that treat patients with kidney failure. The company benefits from a strong, recurring revenue stream and deep vertical integration, which provides a competitive edge in product and service delivery. Its primary growth opportunity lies in the expansion of home-based dialysis, while its main risks include sensitivity to government reimbursement policy and rising labor costs. The stock may suit value-oriented or income-focused investors who prioritize stable demand, though investors should monitor the progress of its ongoing operational transformation and margin recovery efforts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company is a mature player in a slow-growth industry rather than a high-growth tech or biotech firm. |
| Momentum investor | Weak fit | The stock has faced sustained headwinds, lacking the upward trend typically favored by momentum strategies. |
| Value investor | Strong fit | Shares have often traded at valuations that may appeal to investors looking for steady, established healthcare assets. |
| Dividend investor | Strong fit | The company historically provides a consistent dividend yield, supported by the recurring nature of dialysis demand. |
| Low-risk investor | Mixed fit | While the business is essential, regulatory and reimbursement risks introduce volatility that may not suit the most conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Regulatory news and reimbursement changes can cause short-term stock price fluctuations. |
| Valuation risk | Medium | The stock's valuation is tied to long-term reimbursement stability, which is outside the company's direct control. |
| Competition risk (Dialysis Services) | Medium / high | Intense competition for patient volume and labor limits pricing power. |
| Business quality | Strong | The company provides essential, life-sustaining services with high barriers to entry. |
| Dividend income | Medium | Dividends are dependent on maintaining sufficient free cash flow amidst operational restructuring. |
| Execution risk | Medium / high | Successfully executing on transformation and cost-saving initiatives is critical for margin recovery. |
Analysis of Past Performance
Type Stock | Historic Profit -20.53% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.31B USD | Price to earnings Ratio 11.92 | 1Y Target Price 23.84 |
Price to earnings Ratio 11.92 | 1Y Target Price 23.84 | ||
Volume (30-day avg) 1.1M shares | Beta 0.81 | 52 Weeks Range 19.24 - 26.42 | Updated Date 10/30/2026 |
52 Weeks Range 19.24 - 26.42 | Updated Date 10/30/2026 | ||
Dividends yield (FY) 3.77% | Basic EPS (TTM) 1.94 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Health Care Services | Clinical dialysis treatment, laboratory services, and pharmacy services. | Revenue comes from steady, recurring payments for life-sustaining patient treatments. |
| Health Care Products | Dialysis machines, dialyzers, and disposable equipment. | Revenue is generated from the sale of medical hardware and consumables to clinics globally. |
| Geography | Operations spanning North America, EMEA, Latin America, and Asia-Pacific. | The company is globally diversified, which spreads risk but exposes earnings to various healthcare policy regimes. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When Before Market | Estimate 0.53 | Actual - |
Profitability
Profit Margin 4.83% | Operating Margin (TTM) 10.77% |
Management Effectiveness
Return on Assets (TTM) 3.98% | Return on Equity (TTM) 8.52% |
Valuation
Trailing PE 11.92 | Forward PE 8.94 | Enterprise Value 22.62B | Price to Sales(TTM) 0.63 |
Enterprise Value 22.62B | Price to Sales(TTM) 0.63 | ||
Enterprise Value to Revenue 1.05 | Enterprise Value to EBITDA 5.91 | Shares Outstanding 532.22M | Shares Floating 397.12M |
Shares Outstanding 532.22M | Shares Floating 397.12M | ||
Percent Insiders - | Percent Institutions 9.96 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.